Post by JHam on May 15, 2020 16:00:50 GMT
Sorrento Therapeutics just publish pre-clinical data. The stock is running big time. I don’t own any and have no plan to buy, but good news if they can prove this in human trials.
STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies
STI-1499 Antibody has demonstrated in preclinical experiments (full results will be submitted to a peer-reviewed publication shortly):
- 100% inhibition of SARS-CoV-2 virus infection of healthy cells after four days incubation
- Specific binding to S1 subunit of the SARS-CoV-2 Spike protein and complete blockade of its interaction with ACE2 receptor
www.prnewswire.com/news-releases/sti-1499-a-potent-anti-sars-cov-2-antibody-demonstrates-ability-to-completely-inhibit-in-vitro-virus-infection-in-preclinical-studies-301059779.html
STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies
STI-1499 Antibody has demonstrated in preclinical experiments (full results will be submitted to a peer-reviewed publication shortly):
- 100% inhibition of SARS-CoV-2 virus infection of healthy cells after four days incubation
- Specific binding to S1 subunit of the SARS-CoV-2 Spike protein and complete blockade of its interaction with ACE2 receptor
www.prnewswire.com/news-releases/sti-1499-a-potent-anti-sars-cov-2-antibody-demonstrates-ability-to-completely-inhibit-in-vitro-virus-infection-in-preclinical-studies-301059779.html
